Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Stryker’s first quarter of 2026 results were significantly influenced by a cyber incident late in the quarter, which disrupted global business operations and delayed shipments and revenue recognition across its diverse portfolio.</li><li>Despite this interruption, the company reported 2.4% organic sales growth worldwide, with 1.9% growth in the U.S. and 3.9% internationally, reflecting underlying demand resilience and solid market fundamentals.</li><li>The disruption’s impact varied considerably across business lines due to differing go-to-market models, production cycles, and inventory arrangements.</li></ul>

Stryker’s first quarter of 2026 results were significantly influenced by a cyber incident late in the quarter, which disrupted global business operations and delayed shipments and revenue recognition across its diverse portfolio.Despite this interruption, the company reported 2.4% organic sales growth worldwide, with 1.9% growth in the U.S. and 3.9% internationally, reflecting underlying demand resilience and solid market fundamentals.The disruption’s impact varied considerably across business lines due to differing go-to-market models, production cycles, and inventory arrangements.

Stryker: Can 2.1x Leverage Support Both A Recovery And An Active Acquisition Pipeline?

<ul><li>Stryker Corporation delivered strong financial results for both the fourth quarter and the full year 2025, demonstrating solid performance across all key financial metrics.</li><li>Organic sales growth reached 11% for Q4 and 10.3% for the full year, surpassing $25 billion in sales.</li><li>This growth was driven by robust demand across the company’s diverse product portfolio, particularly in its Neurocranial, Endoscopy, Instruments, and Trauma and Extremities businesses.</li></ul>

Stryker Corporation delivered strong financial results for both the fourth quarter and the full year 2025, demonstrating solid performance across all key financial metrics.Organic sales growth reached 11% for Q4 and 10.3% for the full year, surpassing $25 billion in sales.This growth was driven by robust demand across the company’s diverse product portfolio, particularly in its Neurocranial, Endoscopy, Instruments, and Trauma and Extremities businesses.

Stryker’s Quiet Robotics Expansion: How Handheld Surgical Tech Is Unlocking the Next Growth Curve!

<ul><li>Stryker Corporation's third-quarter 2025 earnings results illustrate a landscape of both opportunity and challenge for the company and its investors.</li><li>The company reported a robust organic sales growth of 9.5%, with standout performances in its Orthopaedics division, which saw double-digit growth.</li><li>This is a testament to the company's strong market demand across its various business sectors, including MedSurg and Neurotechnology.</li></ul>

Stryker Corporation's third-quarter 2025 earnings results illustrate a landscape of both opportunity and challenge for the company and its investors.The company reported a robust organic sales growth of 9.5%, with standout performances in its Orthopaedics division, which saw double-digit growth.This is a testament to the company's strong market demand across its various business sectors, including MedSurg and Neurotechnology.

Stryker Corporation Unleashes Mako—Will Robotics Dominate the OR?

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>DeepSeek appears to have turned the chatbot market upside-down, putting pressure on AI-linked stocks. The dust has yet to settle, but the selloff has been largely contained to AI-linked stocks.</li>
<li>The rest of the market did not seem to care; the equal-weighted S&amp;P 500 was roughly flat yesterday.</li>
<li>Additionally, market dynamics remain healthy. Bottom line: as long as the S&amp;P 500 remains above 5600-5670, our long-term outlook remains bullish.</li>
</ul>


DeepSeek appears to have turned the chatbot market upside-down, putting pressure on AI-linked stocks. The dust has yet to settle, but the selloff has been largely contained to AI-linked stocks.
The rest of the market did not seem to care; the equal-weighted S&amp;P 500 was roughly flat yesterday.
Additionally, market dynamics remain healthy. Bottom line: as long as the S&amp;P 500 remains above 5600-5670, our long-term outlook remains bullish.


S&P 500 Testing Prior Breakout Level; Market Dynamics Remain Healthy Despite AI-Linked Weakness

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>This report is almost entirely based on datamined from technical publications related to patents and innovations in the area of Odontology.</li>
<li>The industry will see significant consolidation as mid-sized and smaller players with inspired innovations are be bought out as the industry seeks more cost-efficient distribution channels</li>
<li>Among the listed companies <a href="https://www.smartkarma.com/entities/3-m-co" target="_blank" data-smartkarma-citation="entities:14866:1" rel="noopener">3M Co (MMM US)</a> , <a href="https://www.smartkarma.com/entities/dentsply-international-inc" target="_blank" data-smartkarma-citation="entities:10926:1" rel="noopener">Dentsply International (XRAY US)</a> , <a href="https://www.smartkarma.com/entities/align-technology-inc" target="_blank" data-smartkarma-citation="entities:2817:1" rel="noopener">Align Technology (ALGN US)</a> , <a href="https://www.smartkarma.com/entities/envista-holdings-corp" target="_blank" data-smartkarma-citation="entities:35866:1" rel="noopener">Envista Holdings (NVST US)</a>  &amp; <a href="https://www.smartkarma.com/entities/straumann-holding-ag" target="_blank" data-smartkarma-citation="entities:22493:1" rel="noopener">Straumann Holding (STMN SW)</a> stand out. </li>
</ul>


This report is almost entirely based on datamined from technical publications related to patents and innovations in the area of Odontology.
The industry will see significant consolidation as mid-sized and smaller players with inspired innovations are be bought out as the industry seeks more cost-efficient distribution channels
Among the listed companies 3M Co (MMM US) , Dentsply International (XRAY US) , Align Technology (ALGN US) , Envista Holdings (NVST US)  &amp; Straumann Holding (STMN SW) stand out. 


A Detailed Look Into Innovations in Dentistry

United States

Stryker Corporation develops, manufactures, and markets specialty surgical and medical products.  The Company's products include implants, biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; endoscopic, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Stryker Corp (SYK US)

Stryker: Can 2.1x Leverage Support Both A Recovery And An Active Acquisition Pipeline?

Stryker’s first quarter of 2026 results were significantly influenced by a cyber incident late in the quarter, which disrupted global business...

Baptista Research

Stryker’s Quiet Robotics Expansion: How Handheld Surgical Tech Is Unlocking the Next Growth Curve!

Stryker Corporation delivered strong financial results for both the fourth quarter and the full year 2025, demonstrating solid performance across...

Baptista Research

Stryker Corporation Unleashes Mako—Will Robotics Dominate the OR?

Stryker Corporation's third-quarter 2025 earnings results illustrate a landscape of both opportunity and challenge for the company and its...

Baptista Research

S&P 500 Testing Prior Breakout Level; Market Dynamics Remain Healthy Despite AI-Linked Weakness

$SPX Testing Prior Breakout Level; Market Dynamics Remain Healthy Despite AI-Linked Weakness; $DXY, Treasury yields, and crude oil near-term tops...

Vermilion Research

A Detailed Look Into Innovations in Dentistry

The report highlights the most innovative well-known & lesser-known dental companies driving advancements in digital dentistry, materials,...

Pyari Menon

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)